Mesigyna® once-a-month combined injectable contraceptive: Experience in Latin America

International Federation of Family Planning. Injectable contraception declaration. 1999;1:l. Trussell J. Vaughan B. Contraceptive failure, method related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64–72. Djerassi C. The politics of contraception, Vols 1 and 2. California: Stanford Alumni Association, 1970. Gray, 1980, Patterns of bleeding associated with the use of steroid contraceptives, In: Diczfalusy E, Fraser IS, Webb FTG, eds. Endometrial Bleeding and Steroidal Contraception. Bath: Pitman Press, 14 1982, Facts about injectable contraceptives, Bull WHO, 60, 199 Hall PE. Long-acting injectable formulations. In: Diczfalusy E, Bygdeman M, eds. Fertility Regulation Today and Tomorrow. New York: Serono Symposia Publications, Raven Press, 1987;36:119–41. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction.Task Force on Long-acting Systemic Agents for Fetility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. 1. Contraceptive efficacy and side effects. Contraception 1988,37:1–20. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns. Contraception 1989;40:531–51. Koatsawang, 1994, Once-a-month injectable contraceptives, Contraception, 49, 387, 10.1016/0010-7824(94)90034-5 Sang, 1995, A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. 1. Contraceptive efficacy and side effects, Contraception, 51, 167, 10.1016/0010-7824(95)00013-Z Kesserü, 1991, A multicentred, two-year, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive, Contraception, 44, 589, 10.1016/0010-7824(91)90079-U Newton, 1994, Once-a-month combined injectable contraceptives, J Obstet Gynecol, 14, 2, 10.3109/01443619409027641 Aydinlik S. Open multicenter phase III study with once-a-month injectable contraceptive Mesigyna for a duration of three years. Final results Schering Pharma Research Report No. A357, 1993. Makuch, 1978, Sample size requirements for evaluating a conservative therapy, Can Treat Rep, 62, 1037 Farley, 1986, Life table methods for contraceptive research, Statis Med, 5, 475, 10.1002/sim.4780050512 Word Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final Report. Contraception 1983;28:1–20. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-acting Systemic Agents for Fertility Regulation. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three monthly at 100 mg or 150 mg. I. Contraceptive efficacy and side effects. Contraception 1986;34:223–35. Sang, 1995, A multicentred pahse III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given by intramuscular injection to Chinese women. II. The comparison of bleeding patterns, Contraception, 51, 185, 10.1016/0010-7824(95)00014-2 Fraser, 1994, Vaginal bleeding patterns in women using once-a-month injectable contraceptives, Contraception, 49, 399, 10.1016/0010-7824(94)90035-3